Recent advances and future strategies in first-line treatment of ES-SCLC
Copyright © 2024 Elsevier Ltd. All rights reserved..
Recent advancements in treating extensive-stage small-cell lung cancer (ES-SCLC) have been significantly marked by incorporating immune checkpoint inhibitors (ICIs) into platinum-based chemotherapy, leading to modest yet notable improvements in patient outcomes, which become more evident with longer follow-up. However, critical challenges persist, such as identifying effective biomarkers for accurate patient selection or finding more effective drugs. This review delves into the current and evolving treatment landscape for ES-SCLC, focusing on the most promising therapeutic strategies under investigation. We discuss the latest developments in the use of newer ICIs, antiangiogenic agents, PARP inhibitors (PARPi), lurbinectedin, and anti-DLL3 agents, offering insights into potential future directions in the management of this aggressive cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:200 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 200(2024) vom: 22. Feb., Seite 113581 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gomez-Randulfe, Igor [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 23.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2024.113581 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367906864 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367906864 | ||
| 003 | DE-627 | ||
| 005 | 20240229144252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2024.113581 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM367906864 | ||
| 035 | |a (NLM)38301317 | ||
| 035 | |a (PII)S0959-8049(24)00057-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gomez-Randulfe, Igor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent advances and future strategies in first-line treatment of ES-SCLC |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Recent advancements in treating extensive-stage small-cell lung cancer (ES-SCLC) have been significantly marked by incorporating immune checkpoint inhibitors (ICIs) into platinum-based chemotherapy, leading to modest yet notable improvements in patient outcomes, which become more evident with longer follow-up. However, critical challenges persist, such as identifying effective biomarkers for accurate patient selection or finding more effective drugs. This review delves into the current and evolving treatment landscape for ES-SCLC, focusing on the most promising therapeutic strategies under investigation. We discuss the latest developments in the use of newer ICIs, antiangiogenic agents, PARP inhibitors (PARPi), lurbinectedin, and anti-DLL3 agents, offering insights into potential future directions in the management of this aggressive cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antiangiogenic | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Immune checkpoint inhibitors (ICIs) | |
| 650 | 4 | |a Lurbinectedin | |
| 650 | 4 | |a PARP inhibitors | |
| 650 | 4 | |a Small-cell lung cancer (SCLC) | |
| 650 | 7 | |a Angiogenesis Inhibitors |2 NLM | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a Platinum |2 NLM | |
| 650 | 7 | |a 49DFR088MY |2 NLM | |
| 700 | 1 | |a Leporati, Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Brinda |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Califano, Raffaele |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 200(2024) vom: 22. Feb., Seite 113581 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:200 |g year:2024 |g day:22 |g month:02 |g pages:113581 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2024.113581 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 200 |j 2024 |b 22 |c 02 |h 113581 | ||